{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:48:32Z","timestamp":1768895312756,"version":"3.49.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/jac\/dkx091","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T20:10:14Z","timestamp":1488571814000},"page":"2075-2082","source":"Crossref","is-referenced-by-count":14,"title":["An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs"],"prefix":"10.1093","volume":"72","author":[{"given":"Erasmus","family":"Smit","sequence":"first","affiliation":[{"name":"Public Health Laboratory Birmingham, Public Health England, Heartlands Hospital, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"White","sequence":"additional","affiliation":[{"name":"MRC CTU at UCL, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Clark","sequence":"additional","affiliation":[{"name":"Barts and The London NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Churchill","sequence":"additional","affiliation":[{"name":"Brighton and Sussex University Hospitals NHS Trust, Brighton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Public Health Laboratory Cambridge, Public Health England, Addenbrooke\u2019s Hospital, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Collins","sequence":"additional","affiliation":[{"name":"HIV i-Base, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[{"name":"Research Department of Infection, Division of Infection and Immunity, University College London, London, UK"},{"name":"Wellcome Trust Africa Centre for Health and Population Sciences, University of KwaZulu Natal, Mtubatuba, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Sabin","sequence":"additional","affiliation":[{"name":"Research Department of Infection and Population Health London, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Jose","sequence":"additional","affiliation":[{"name":"Research Department of Infection and Population Health London, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tostevin","sequence":"additional","affiliation":[{"name":"Research Department of Infection and Population Health London, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Research Department of Infection and Population Health London, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"key\n\t\t\t\t20180328155835_dkx091-B1","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase I\/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults","volume":"45","author":"Barditch-Crovo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/AAC.38.2.275","article-title":"Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2\u2032,3\u2032-dideoxycytidine and 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine","volume":"38","author":"Gu","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B3","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1128\/AAC.39.8.1888","article-title":"K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine","volume":"39","author":"Gu","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B4","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1128\/JVI.77.10.5685-5693.2003","article-title":"A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation","volume":"77","author":"Garc\u00eda-Lerma","year":"2003","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B5","doi-asserted-by":"crossref","first-page":"565.","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"TenoRes Study Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B6","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B7","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/JVI.01349-08","article-title":"Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1","volume":"83","author":"Coutsinos","year":"2009","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/AAC.01668-12","article-title":"HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir","volume":"57","author":"Theys","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1086\/528863","article-title":"Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir","volume":"46","author":"von Wyl","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B10","author":"WHO"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B11","first-page":"6","article-title":"Update of the drug resistance mutations in HIV-1: March 2013","volume":"21","author":"Johnson","year":"2013","journal-title":"Top Antivir Med"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B12","doi-asserted-by":"crossref","first-page":"313.","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006","article-title":"Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection","volume":"139","author":"Squires","year":"2003","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00126334-200108150-00005","article-title":"Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408","volume":"27","author":"Miller","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350601100209","article-title":"The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations","volume":"11","author":"White","year":"2006","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1128\/AAC.49.3.1139-1144.2005","article-title":"In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase","volume":"49","author":"Parikh","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/nar\/gkp455","article-title":"A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences","volume":"37","author":"Alcantara","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B17","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/bioinformatics\/bti607","article-title":"An automated genotyping system for analysis of HIV-1 and other microbial sequences","volume":"21","author":"de Oliveira","year":"2005","journal-title":"Bioinformatics"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B18","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1086\/605894","article-title":"Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C","volume":"200","author":"Invernizzi","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B19","doi-asserted-by":"crossref","first-page":"e20208.","DOI":"10.1371\/journal.pone.0020208","article-title":"A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1","volume":"6","author":"Coutsinos","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B20","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1086\/588045","article-title":"Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir","volume":"46","author":"Mendoza","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jinf.2013.09.005","article-title":"The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort","volume":"68","author":"Bulteel","year":"2014","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B22","first-page":"2197","article-title":"Evolution of the K65R, K103N and M184V\/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010","volume":"68","author":"Charpentier","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B23","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1089\/aid.2011.0142","article-title":"Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy","volume":"28","author":"Santoro","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/cid\/cis254","article-title":"Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies","volume":"54","author":"Hamers","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP2652","article-title":"Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa","volume":"18","author":"Hoffmann","year":"2013","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B26","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","article-title":"High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen","volume":"26","author":"Sunpath","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B27","doi-asserted-by":"crossref","first-page":"e0118145.","DOI":"10.1371\/journal.pone.0118145","article-title":"High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa","volume":"10","author":"Skhosana","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B28","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/cid\/civ102","article-title":"Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial","volume":"60","author":"Kantor","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B29","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(16)00023-0","article-title":"Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden","volume":"3","author":"H\u00e4ggblom","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/infdis\/jiw213","article-title":"No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom","volume":"214","author":"White","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/infdis\/jiw214","article-title":"HIV-1 subtype C, tenofovir, and the relationship with treatment failure and drug resistance","volume":"214","author":"G\u00fcnthard","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/135965350701200806","article-title":"Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation","volume":"12","author":"Antinori","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B33","first-page":"1211","article-title":"Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis","volume":"211","author":"Lehman","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/aid.2008.0159","article-title":"Dynamics of NRTI resistance mutations during therapy interruption","volume":"25","author":"Trignetti","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180328155835_dkx091-B35","first-page":"187","article-title":"Minority HIV-1 drug-resistant mutations and prevention of mother-to-child transmission: perspectives for resource-limited countries","volume":"16","author":"Samuel","year":"2014","journal-title":"AIDS Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/7\/2075\/24332395\/dkx091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T04:34:17Z","timestamp":1658723657000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/72\/7\/2075\/3098563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,4,3]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx091","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,4,3]]}}}